SapVax Achieves Technical Milestone, Raises Additional Funding, and Expands Advisory Board

SapVax, LLC, a privately-held biotechnology startup developing a suite of cancer vaccines based on novel self-adjuvanting peptide technology, announced today that it achieved a significant proof-of-principle milestone, expanded its Scientific Advisory Board, and closed a new round of equity financing to continue to advance its unique platform towards the clinic.